Kodiak Sciences Inc. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Kodiak Sciences performed this year. Think of this as a "cheat sheet" to help you decide if this company fits your investment goals.

1. What does this company do?

Kodiak Sciences is a biotech company based in Palo Alto, California. They develop new treatments for common eye diseases, such as wet age-related macular degeneration and diabetic macular edema. Because they are still in the research phase, they make no money from product sales. Their business relies on the "ABC Platform," which aims to create medicines that last longer in the eye, potentially requiring fewer injections for patients.

2. Financial health: The "Going Concern" warning

This is the most important part of the report: The company has officially warned that they may not be able to stay in business.

As of December 31, 2023, the company had lost about $1.1 billion since its inception. In 2023 alone, they lost $232.5 million, mostly due to $167.4 million in research costs. With $237.5 million in cash left at year-end, their current spending suggests they have a limited amount of time before they run out of money. They generate no revenue, so their survival depends on raising more cash through selling stock, taking on debt, or finding partners. As of mid-2025, the market value of their public stock was about $121.6 million, reflecting investor doubt about their future.

3. Major wins and challenges

Kodiak is now focusing on three main drug candidates: Tarcocimab tedromer, KSI-501, and KSI-101.

• The Goal: Pass Phase 3 clinical trials to win FDA approval. After previous trials for Tarcocimab failed to meet their goals, the company shifted its focus to the "GLOW" and "DAYBREAK" study designs for their newer candidates.
• The Challenge: Drug development is a high-stakes gamble. The company cut back its research pipeline to save cash, ending several early-stage programs. Because money is tight, they must prioritize the drugs most likely to succeed. Any failure in current trials for KSI-501 or KSI-101 would likely be devastating for the company’s value.

4. Key risks for your wallet

• The "All-or-Nothing" Risk: Since they have no products to sell, the stock price depends entirely on clinical trial results. A single failure—like their previous Tarcocimab trials—can cause the stock price to crash overnight.
• Dilution: To pay for operations, Kodiak frequently sells more shares. In 2023 and early 2024, they issued millions of new shares. This reduces your ownership percentage and often drives the stock price down.
• Regulatory Hurdles: The FDA requires strict proof that drugs are safe and effective. A formal rejection or a request for more expensive trials would likely drain the company's remaining cash before they reach the market.

5. Future outlook

The company is pushing forward, but they are in a tight spot. Watch for news on "additional financing," such as stock sales or deals with larger pharmaceutical companies. If they cannot raise more money or hit a major clinical milestone, they may struggle to fund the trials needed to reach the market.

Decision-making tip: Before investing, ask yourself if you are comfortable with a company that has no revenue and is actively warning investors about its ability to stay afloat. If you are looking for stability, this type of high-risk biotech stock may not be the right fit for your portfolio.

Disclaimer: I am an AI, not a financial advisor. Biotech stocks are extremely volatile. Always do your own research before investing.